DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
Zepbound (tirzepatide 5–15mg) costs $549/month via LillyDirect direct cash-pay, $25/month with insurance + savings card, or up to $1,349/month retail. Updated for 2026.
Same drug, different pricing channels. The spread is often $800-1000/month between cheapest and retail cash.
| Channel | Source | |
|---|---|---|
Cash-pharmacy + savings card Commercially insured with coverage — manufacturer copay card (GoodRx/SingleCare style discount otherwise). | $25 with commercial insurance + savings cardBest value | Manufacturer savings card terms |
With insurance (covered, after PA) Commercial plan that covers the drug after prior authorization — copay depends on your tier. | $25/month – $150/month | Plan formulary copay tiers |
Compounded (telehealth, where legal) Cash-pay via 503A pharmacy telehealth. Not FDA-approved as the brand — regulatory wind-down ongoing. | $249–$349/month | Compounded tirzepatide via Hims/Ro |
Manufacturer cash — LillyDirect direct cash-pay Anyone with a valid prescription who pays cash — no insurance required, valid in all 50 states. | $549/monthLowest | LillyDirect |
Retail / list (cash, no programs) Walk-in pharmacy price with no insurance, savings card, or manufacturer program. | $1,349/monthList price | WAC / pharmacy list, LoseLab pricing desk |
Cheapest mfg cash price today is $549/mo. We’ll email you the day it gets cheaper — no spam, unsubscribe anytime.
Zepbound retail cash-pay is $1,349 per month. LillyDirect direct cash-pay reduces this to $549/month for the maintenance dose (5mg+) or $399/month for the 2.5mg starter dose. LillyDirect ships from Lilly's direct pharmacy — same FDA-approved Zepbound, no middleman markup.
Lowest observed cash-pay ranges from our state cost matrix. Where you fill changes the price.
If your commercial insurance covers Zepbound after PA, the Lilly savings card brings the copay as low as $25/month for up to 12 months. Standard out-of-pocket without the savings card runs $50–$150/month depending on tier. The OSA-with-obesity FDA indication (December 2024) makes Zepbound easier to approve than Wegovy on many plans.
Three programs reduce Zepbound cost: (1) Lilly savings card — $25/month if commercially insured, valid 12 months; (2) LillyDirect direct cash-pay — $549/month maintenance or $399/month starter, no insurance required; (3) Patient assistance for income-eligible uninsured.
Medicare Part D historically excluded weight-loss tirzepatide. The OSA-with-obesity FDA indication (December 2024) opened a coverage pathway for Medicare Advantage members with documented sleep apnea (AHI ≥15) plus obesity.
Medicaid coverage varies by state. As of 2026, fewer than 12 states cover Zepbound for weight loss. The OSA indication unlocks coverage on additional plans — submit sleep study + obesity ICD-10 together for fastest approval.
$249–$349/month — same active ingredient (tirzepatide), not FDA-approved as Zepbound. 503A pharmacy compounding. FDA enforcement risk after shortage end.
$499/month via NovoCare direct — different molecule, more cardiovascular outcomes data via SELECT trial. Lower weight loss in head-to-head trial.
Same molecule as Zepbound but FDA-approved for type 2 diabetes only. Off-label weight-loss prescribing increasingly denied in 2026.
Zepbound out-of-pocket cost ranges from $25/month (covered + savings card) to $1,349/month (retail). The realistic cash-pay floor is $399/month for starter dose via LillyDirect, or $549/month for maintenance. If you have sleep apnea, the OSA pathway dramatically improves coverage odds.
Read full Zepbound review →Pricing verified monthly against current manufacturer and pharmacy formularies. Coverage rules vary by plan — verify against your member portal before prescribing.